PUBLICATIONS

This section contains information about I-O Optimise publications.

I-O Optimise rationale and methodology publications

I-O Optimise data publications

  • P Horvat, A Mette-Kejs, Q Ann, V Lascano, B Bray, D Patel, S Ekman, L Lacoin, A Juarez-Garcia, J Kim. Swedish National Registries vs Electric Health Records: Comparing the completeness of systemic therapy data using data from the SCAN‐LEAF study. Presented at the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 24–28 August 2019, Philadelphia, PA, USA. Poster 424.
    P Horvat, et al. Pharmacoepidemiol Drug Saf. 2019;28(S2):5–586 https://doi.org/10.1002/pds.4864
  • M Snee, S Cheeseman, M Thompson, R Bowman, L Lacoin, W Sopwith, C Chaib, A Juarez-Garcia, M Daumont, JR Penrod, JC O'Donnell, G Hall. Small cell lung cancer (SCLC) treatment and survival in the UK: a REAL-Oncology analysis from the I-O Optimise initiative. Presented at the IASLC 20th World Conference on Lung Cancer (WCLC 2019), 7–10 September 2019, Barcelona, Spain. Poster P2.12-01.
    M Snee, et al. Journal of Thoracic Oncology. 2019;14(10):S812 https://doi.org/10.1016/j.jtho.2019.08.1746
  • MAS Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Goncalves. Small cell lung cancer (SCLC) treatment and survival in Portugal: An IPO-PORTO analysis from the I-O Optimise initiative. Presented at the IASLC 20th World Conference on Lung Cancer (WCLC 2019), 7–10 September 2019, Barcelona, Spain. Poster P2.12-19.
    M Soares, et al. Journal of Thoracic Oncology. 2019;14(10):S820-S821 https://doi.org/10.1016/j.jtho.2019.08.1764
  • M Snee, S Cheeseman, M Thompson, R Bowman, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, JC O’Donnell, G Hall. Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: A REAL-oncology analysis from the I-O Optimise initiative. Presented at the European Society for Medical Oncology (ESMO) 2019 Congress, 27 September – 1 October 2019, Barcelona, Spain. Poster 1501P.
    M Snee, et al. Annals of Oncology. 2019;30(Suppl 5):mdz260.023 https://doi.org/10.1093/annonc/mdz260.023
  • M Snee, S Cheeseman, M Thompson, M Riaz, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, JC O’Donnell, G Hall. Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: a REAL-Oncology database analysis from the I-O Optimise initiative. Presented at the 9th Annual European Lung Cancer Congress, 10–13 April 2019, Geneva, Switzerland. Poster 44P.
    M Snee, et al. Annals of Oncology. 2019;30(Suppl 2) https://doi.org/10.1093/annonc/mdz070.002
  • MAS Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O’Donnell, MJ Bento, F Rocha Gonçalves. Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: an IPO-PORTO database analysis from the I-O Optimise initiative. Presented at the 9th Annual European Lung Cancer Congress, 10–13 April 2019, Geneva, Switzerland. Poster 45P.
    MAS Soares, et al. Annals of Oncology. 2019;30(Suppl 2) https://doi.org/10.1093/annonc/mdz070.003 Encored at the 16.° Congresso Nacional de Oncologia 2019, 28–30 November 2019, Estoril, Portugal. [Padrões de tratamento (Tx) e sobrevivência global (SG) em doentes (dts) com CPCNP, estadios IIIB–IV, em Portugal: análise de dados da iniciativa I-O Optimise]
  • JB Sørensen, S Ekman, O Terje Brustugun, P Horvat, D Patel, M Rosenlund, A Mette Kejs, A Juarez-Garcia, M Daumont, L Lacoin, JR Penrod, JC O’Donnell, M Planck. Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative. Presented at the 9th Annual European Lung Cancer Congress, 10–13 April 2019, Geneva, Switzerland. Poster 46P.
    JB Sørensen, et al. Annals of Oncology. 2019;30(Suppl 2) https://doi.org/10.1093/annonc/mdz070.004
  • S Ekman, JB Sørensen, O Terje Brustugun, P Horvat, D Patel, M Rosenlund, A Mette Kejs, A Juarez-Garcia, M Daumont, L Lacoin, JR Penrod, JC O’Donnell, M Planck. Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative. Presented at the 9th Annual European Lung Cancer Congress, 10–13 April 2019, Geneva, Switzerland. Poster 47P.
    S Ekman, et al. Annals of Oncology. 2019;30(Suppl 2) https://doi.org/10.1093/annonc/mdz070.005
  • M Daumont, S Ekman, M Planck, OT Brustugun, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, HC Jacobs, L Lacoin, JB Sørensen. Healthcare resource utilisation among patients with non-small cell lung cancer (NSCLC) in Sweden: the SCAN-LEAF study. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual European Congress, 10–14 November 2018, Barcelona, Spain. Poster PCN258.
    M Daumont, et al. Value in Health. 2018;21(Suppl 3):PS58 https://doi.org/10.1016/j.jval.2018.09.340
  • JB Sørensen, S Ekman, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, M Daumont, HC Jacobs, L Lacoin, OT Brustugun, M Planck. Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005–2015: the SCAN-LEAF study. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, 19–23 October 2018, Munich, Germany. Poster 1483P.
    JB Sørensen, et al. Annals of Oncology. 2018;29(Suppl 8):viii493–viii547 https://doi.org/10.1093/annonc/mdy292.104
  • S Ekman, M Planck, JB Sørensen, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, M Daumont, HC Jacobs, L Lacoin, OT Brustugun. Treatment patterns in patients (pts) with stage IIIB–IV non-small cell lung cancer (NSCLC) in Sweden: the SCAN-LEAF study. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, 19–23 October 2018, Munich, Germany. Poster 1484P.
    S Ekman, et al. Annals of Oncology. 2018;29(Suppl 8):viii493–viii547 https://doi.org/10.1093/annonc/mdy292.105
  • M Snee, S Cheeseman, M Thompson, M Riaz, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, J O’Donnell, G Hall. Treatment patterns in patients with stage IIIB–IV NSCLC in clinical practice: retrospective analysis of a UK trust database. Presented at the IASLC 19th World Conference on Lung Cancer (WCLC 2018), 23–26 September 2018, Toronto, Canada. Poster P2.01-91.
    M Snee, et al. Journal of Thoracic Oncology. 2018;13(10):S700 https://doi.org/10.1016/j.jtho.2018.08.1145 Encored at the British Thoracic Society (BTS) Winter Meeting 2018, 5–7 December 2018, London, UK. Poster P82.
    M Snee, et al. Thorax. 2018;73(Suppl 4):A145-A146 https://thorax.bmj.com/content/73/Suppl_4/A145.2
  • M Snee, S Cheeseman, M Thompson, P Godden, W Sopwith, C Chaib, A Juarez-Garcia, L Lacoin, JR Penrod, G Hall. Clinical characteristics and overall survival of patients diagnosed with non-small cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical practice: a retrospective analysis of a UK hospital database. Presented at the 16th Annual British Thoracic Oncology Group (BTOG) Conference, 24–26 January 2018, Dublin, Ireland. Poster 92.
    M Snee, et al. Lung Cancer. 2018;115(Suppl 1):S38 https://doi.org/10.1016/S0169-5002(18)30118-1 Encored at the 33rd German Cancer Congress (Deutscher Krebskongress) (DKK) 2018, 21–24 February 2018, Berlin, Germany. Poster 1036.
    M Snee, et al. Oncology Research and Treatment. 2018;41(Suppl 1):1–221 https://doi.org/10.1159/000487109
  • I Durand-Zaleski, M Manley-Daumont, P Baas, C Chaib, D Chao, C Chouaid, S Ekman, T d’Estrubé, F Griesinger, A Juarez-Garcia, M Khovratovich, D Layton, A McNamara, JC O’Donnell, JR Penrod, M Pereira, HT Sørensen. I-O Optimise: developing a unique multinational real-world evidence-based research platform in oncology. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 4–8 November 2017, Glasgow, Scotland. Poster PRM69.
    I Durand-Zaleski, et al. Value in Health. 2017;20(9):A742–A743 https://doi.org/10.1016/j.jval.2017.08.2055
  • M Sandelin, M Planck, JB Sørensen, OT Brustugun, J Rockberg, A Juarez-Garcia, D Layton, M Manley-Daumont, H Huang, M Pereira, J Svärd, M Rosenlund, O Chirita, L Jørgensen, S Ekman. Non‐small cell lung cancer (NSCLC) patient characteristics and clinical care insights in Sweden: the SCAN‐LEAF study. Presented at the IASLC 18th World Conference on Lung Cancer (WCLC 2017), 15–18 October 2017, Yokohama, Japan. Poster P1.06-012.
    M Sandelin, et al. Journal of Thoracic Oncology. 2017;12(11 Suppl 2):S1990 https://doi.org/10.1016/j.jtho.2017.09.906
  • S Ekman, M Planck, OT Brustugun, J Rockberg, A Juarez-Garcia, M Manley-Daumont, H Huang, M Pereira, J Svärd, M Rosenlund, O Chirita, L Jørgensen, M Sandelin, JB Sørensen. Non-small cell lung cancer (NSCLC) treatment and survival in Scandinavia: the SCAN-LEAF study. Presented at the IASLC 18th World Conference on Lung Cancer (WCLC 2017), 15–18 October 2017, Yokohama, Japan. Oral MA 18.14.
    S Ekman, et al. Journal of Thoracic Oncology. 2017;12(11 Suppl 2):S1881–S1882 https://doi.org/10.1016/j.jtho.2017.09.632
  • S Ekman, JB Sørensen, J Rockberg, M Sandelin, M Daumont, P Sobocki, P Klint, H-Y Huang, J Svärd, O Chirita, L Jørgensen, M Planck. Overall survival and intermediate outcomes among Scandinavian non-small cell lung cancer patients: the SCAN-LEAF study. Presented at the IASLC 17th World Conference on Lung Cancer (WCLC 2016), 4–7 December 2016, Vienna, Austria. Poster P1.06-041.
    S Ekman, et al. Journal of Thoracic Oncology. 2017;12(1 Suppl):S691 https://doi.org/10.1016/j.jtho.2016.11.905